QurAlis
Cambridge
About QurAlis
QurAlis is a clinical-stage biotechnology company that is developing precision medicines with genetically validated targets for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Its proprietary platforms and biomarkers allow for the design and development of drugs that target disease-causing genetic alterations directly.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $135.5M
- Funding stage: Early Stage Venture
- Last round: Series B (Mar 2023)
- Website: quralis.com
- Phone: 781-816-7031
Industries & Categories
Biotechnology, Genetics, Health Care, Precision Medicine, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/quralis-14186 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.